2020
Syndecan-1 and KRAS Gene Expression Signature Associates With Patient Survival in Pancreatic Cancer.
Wu Y, Huang H, Fervers B, Lu L. Syndecan-1 and KRAS Gene Expression Signature Associates With Patient Survival in Pancreatic Cancer. Pancreas 2020, 49: 1187-1194. PMID: 32898003, DOI: 10.1097/mpa.0000000000001654.Peer-Reviewed Original ResearchConceptsSyndecan-1Patient survivalPancreatic cancerAdjusted hazard ratioPancreatic cancer patientsKRAS somatic mutationsSDC1 mRNASomatic mutationsHazard ratioCancer patientsClinical dataSurvival analysisKRASPatientsKyoto EncyclopediaKRAS mRNAElevated mortalityGenomes (KEGG) pathway analysisCancerPathway analysisLower methylationMolecular characteristicsSurvivalMRNANegative correlationBayesian copy number detection and association in large-scale studies
Cristiano S, McKean D, Carey J, Bracci P, Brennan P, Chou M, Du M, Gallinger S, Goggins MG, Hassan MM, Hung RJ, Kurtz RC, Li D, Lu L, Neale R, Olson S, Petersen G, Rabe KG, Fu J, Risch H, Rosner GL, Ruczinski I, Klein AP, Scharpf RB. Bayesian copy number detection and association in large-scale studies. BMC Cancer 2020, 20: 856. PMID: 32894098, PMCID: PMC7487704, DOI: 10.1186/s12885-020-07304-3.Peer-Reviewed Original Research
2019
Current Approaches to Pancreatic Cancer Screening
Chhoda A, Lu L, Clerkin BM, Risch H, Farrell JJ. Current Approaches to Pancreatic Cancer Screening. American Journal Of Pathology 2019, 189: 22-35. PMID: 30558719, DOI: 10.1016/j.ajpath.2018.09.013.BooksMeSH KeywordsCarcinoma, Pancreatic DuctalEarly Detection of CancerGenetic Predisposition to DiseaseHumansPancreatic NeoplasmsRisk FactorsConceptsPancreatic ductal adenocarcinomaHigh-risk individualsRisk factorsCancer syndromesHereditary breast-ovarian cancer syndromeBreast-ovarian cancer syndromeEarly resectable stagePancreatic cancer screeningScreening strategyFamilial atypical multipleCancer-related deathOvarian cancer syndromeCurrent screening strategiesLi-Fraumeni syndromePeutz-Jeghers syndromeGenetic risk factorsResectable stageCancer screeningPancreatic cancerChronic diseasesDuctal adenocarcinomaLynch syndromePrecursor lesionsLower incidenceFamilial history
2018
Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer
Walsh N, Zhang H, Hyland PL, Yang Q, Mocci E, Zhang M, Childs EJ, Collins I, Wang Z, Arslan AA, Beane-Freeman L, Bracci PM, Brennan P, Canzian F, Duell EJ, Gallinger S, Giles GG, Goggins M, Goodman GE, Goodman PJ, Hung RJ, Kooperberg C, Kurtz RC, Malats N, LeMarchand L, Neale RE, Olson SH, Scelo G, Shu XO, Van Den Eeden SK, Visvanathan K, White E, Zheng W, consortia P, Albanes D, Andreotti G, Babic A, Bamlet W, Berndt S, Borgida A, Boutron-Ruault M, Brais L, Brennan P, Bueno-de-Mesquita B, Buring J, Chaffee K, Chanock S, Cleary S, Cotterchio M, Foretova L, Fuchs C, Gaziano J, Giovannucci E, Goggins M, Hackert T, Haiman C, Hartge P, Hasan M, Helzlsouer K, Herman J, Holcatova I, Holly E, Hoover R, Hung R, Janout V, Klein E, Kurtz R, Laheru D, Lee I, Lu L, Malats N, Mannisto S, Milne R, Oberg A, Orlow I, Patel A, Peters U, Porta M, Real F, Rothman N, Sesso H, Severi G, Silverman D, Strobel O, Sund M, Thornquist M, Tobias G, Wactawski-Wende J, Wareham N, Weiderpass E, Wentzensen N, Wheeler W, Yu H, Zeleniuch-Jacquotte A, Kraft P, Li D, Jacobs E, Petersen G, Wolpin B, Risch H, Amundadottir L, Yu K, Klein A, Stolzenberg-Solomon R. Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer. Journal Of The National Cancer Institute 2018, 111: 557-567. PMID: 30541042, PMCID: PMC6579744, DOI: 10.1093/jnci/djy155.Peer-Reviewed Original ResearchConceptsGenome-wide association studiesGene setsSingle nucleotide polymorphismsFunctional annotationEpidermal growth factor receptor transactivationExpression quantitative trait loci (eQTL) analysisQuantitative trait locus (QTL) analysisGrowth factor receptor transactivationTop single nucleotide polymorphismsG protein-coupled receptorsGene-set analysisProtein-coupled receptorsIndividual single nucleotide polymorphismsBeta-cell developmentEQTL analysisGWAS dataPCC genesPancreatic ductal adenocarcinomaReceptor transactivationLocus analysisPathway analysisAssociation studiesGenesSusceptibility genesIdentifies associationsGenome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer
Klein AP, Wolpin BM, Risch HA, Stolzenberg-Solomon RZ, Mocci E, Zhang M, Canzian F, Childs EJ, Hoskins JW, Jermusyk A, Zhong J, Chen F, Albanes D, Andreotti G, Arslan AA, Babic A, Bamlet WR, Beane-Freeman L, Berndt SI, Blackford A, Borges M, Borgida A, Bracci PM, Brais L, Brennan P, Brenner H, Bueno-de-Mesquita B, Buring J, Campa D, Capurso G, Cavestro GM, Chaffee KG, Chung CC, Cleary S, Cotterchio M, Dijk F, Duell EJ, Foretova L, Fuchs C, Funel N, Gallinger S, M. Gaziano JM, Gazouli M, Giles GG, Giovannucci E, Goggins M, Goodman GE, Goodman PJ, Hackert T, Haiman C, Hartge P, Hasan M, Hegyi P, Helzlsouer KJ, Herman J, Holcatova I, Holly EA, Hoover R, Hung RJ, Jacobs EJ, Jamroziak K, Janout V, Kaaks R, Khaw KT, Klein EA, Kogevinas M, Kooperberg C, Kulke MH, Kupcinskas J, Kurtz RJ, Laheru D, Landi S, Lawlor RT, Lee I, LeMarchand L, Lu L, Malats N, Mambrini A, Mannisto S, Milne RL, Mohelníková-Duchoňová B, Neale RE, Neoptolemos JP, Oberg AL, Olson SH, Orlow I, Pasquali C, Patel AV, Peters U, Pezzilli R, Porta M, Real FX, Rothman N, Scelo G, Sesso HD, Severi G, Shu XO, Silverman D, Smith JP, Soucek P, Sund M, Talar-Wojnarowska R, Tavano F, Thornquist MD, Tobias GS, Van Den Eeden SK, Vashist Y, Visvanathan K, Vodicka P, Wactawski-Wende J, Wang Z, Wentzensen N, White E, Yu H, Yu K, Zeleniuch-Jacquotte A, Zheng W, Kraft P, Li D, Chanock S, Obazee O, Petersen GM, Amundadottir LT. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Nature Communications 2018, 9: 556. PMID: 29422604, PMCID: PMC5805680, DOI: 10.1038/s41467-018-02942-5.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Pancreatic DuctalDatabases, GeneticGenetic Predisposition to DiseaseGenome-Wide Association StudyHepatocyte Nuclear Factor 1-betaHepatocyte Nuclear Factor 4HumansIntercellular Signaling Peptides and ProteinsIntracellular Signaling Peptides and ProteinsPancreatic NeoplasmsPolymorphism, Single NucleotideProteinsRepressor ProteinsTensinsConceptsNew genome-wide significant lociGenome-wide significant lociExpression quantitative trait loci (eQTL) analysisQuantitative trait locus (QTL) analysisPANcreatic Disease ReseArch (PANDoRA) consortiumNew susceptibility lociPancreatic cancer susceptibility genesCommon susceptibility allelesCancer susceptibility genesSignificant lociPancreatic Cancer Case-Control ConsortiumMolecular supportPancreatic Cancer Cohort ConsortiumLocus analysisSusceptibility lociSusceptibility genesSusceptibility allelesEuropean ancestryNovel associationsLociPancreatic cancerConsortiumGWASGenesAlleles
2017
Aspirin Use and Reduced Risk of Pancreatic Cancer
Risch HA, Lu L, Streicher SA, Wang J, Zhang W, Ni Q, Kidd MS, Yu H, Gao YT. Aspirin Use and Reduced Risk of Pancreatic Cancer. Cancer Epidemiology Biomarkers & Prevention 2017, 26: 68-74. PMID: 27999143, PMCID: PMC5225096, DOI: 10.1158/1055-9965.epi-16-0508.Peer-Reviewed Original ResearchConceptsPancreatic cancerAspirin useRegular useConfidence intervalsLong-term aspirin useControl subjects frequencyLow-dose aspirinAvoidance of smokingBody mass indexPopulation-based studyUnconditional logistic regressionABO blood groupRisk-benefit analysisAspirin typeCagA seropositivityDiabetes mellitusMass indexCigarette smokingCardiovascular diseaseAspirinCancerCertain cancersLogistic regressionBlood groupSubjects frequency
2016
Exosomes: potential for early detection in pancreatic cancer
Lu L, Risch HA. Exosomes: potential for early detection in pancreatic cancer. Future Oncology 2016, 12: 1081-1090. PMID: 26860951, DOI: 10.2217/fon-2015-0005.Peer-Reviewed Original Research
2015
Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer
Childs EJ, Mocci E, Campa D, Bracci PM, Gallinger S, Goggins M, Li D, Neale RE, Olson SH, Scelo G, Amundadottir LT, Bamlet WR, Bijlsma MF, Blackford A, Borges M, Brennan P, Brenner H, Bueno-de-Mesquita HB, Canzian F, Capurso G, Cavestro GM, Chaffee KG, Chanock SJ, Cleary SP, Cotterchio M, Foretova L, Fuchs C, Funel N, Gazouli M, Hassan M, Herman JM, Holcatova I, Holly EA, Hoover RN, Hung RJ, Janout V, Key TJ, Kupcinskas J, Kurtz RC, Landi S, Lu L, Malecka-Panas E, Mambrini A, Mohelnikova-Duchonova B, Neoptolemos JP, Oberg AL, Orlow I, Pasquali C, Pezzilli R, Rizzato C, Saldia A, Scarpa A, Stolzenberg-Solomon RZ, Strobel O, Tavano F, Vashist YK, Vodicka P, Wolpin BM, Yu H, Petersen GM, Risch HA, Klein AP. Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Nature Genetics 2015, 47: 911-916. PMID: 26098869, PMCID: PMC4520746, DOI: 10.1038/ng.3341.Peer-Reviewed Original ResearchMeSH KeywordsAgedAustraliaChromosomes, Human, Pair 17Chromosomes, Human, Pair 2Chromosomes, Human, Pair 3Chromosomes, Human, Pair 7EuropeFemaleGene FrequencyGenetic LociGenetic Predisposition to DiseaseGenome-Wide Association StudyGenotypeHumansMaleMiddle AgedNorth AmericaPancreatic NeoplasmsPolymorphism, Single NucleotideRisk FactorsRisch et al. Respond to “Clinical Utility of Prediction Models for Rare Outcomes: The Example of Pancreatic Cancer”
Risch HA, Yu H, Lu L, Kidd MS. Risch et al. Respond to “Clinical Utility of Prediction Models for Rare Outcomes: The Example of Pancreatic Cancer”. American Journal Of Epidemiology 2015, 182: 39-40. PMID: 26049861, DOI: 10.1093/aje/kwv025.Peer-Reviewed Original ResearchDetectable Symptomatology Preceding the Diagnosis of Pancreatic Cancer and Absolute Risk of Pancreatic Cancer Diagnosis
Risch HA, Yu H, Lu L, Kidd MS. Detectable Symptomatology Preceding the Diagnosis of Pancreatic Cancer and Absolute Risk of Pancreatic Cancer Diagnosis. American Journal Of Epidemiology 2015, 182: 26-34. PMID: 26049860, PMCID: PMC4479115, DOI: 10.1093/aje/kwv026.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCarcinomaCase-Control StudiesConnecticutHumansMiddle AgedModels, StatisticalPancreatic NeoplasmsRisk AssessmentSEER ProgramConceptsPancreatic cancer diagnosisAbsolute riskPancreatic cancerRecent diagnosisRisk factorsEnd Results (SEER) incidence dataUS Surveillance EpidemiologyCancer diagnosisCurrent cigarette smokingLow lifetime riskABO blood groupDiabetes mellitusSurveillance EpidemiologyCigarette smokingSurvival durationLifetime riskHigh riskPancreatic causesCancerBlood groupRisk estimatesDiagnosisIncidence dataSymptomatologyRiskVitamin D and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Case–Control Consortium
Waterhouse M, Risch HA, Bosetti C, Anderson KE, Petersen GM, Bamlet WR, Cotterchio M, Cleary SP, Ibiebele TI, La Vecchia C, Skinner HG, Strayer L, Bracci PM, Maisonneuve P, Bueno-de-Mesquita HB, Zaton Ski W, Lu L, Yu H, Janik-Koncewicz K, Polesel J, Serraino D, Neale RE. Vitamin D and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Case–Control Consortium. Annals Of Oncology 2015, 26: 1776-1783. PMID: 25977560, PMCID: PMC4511221, DOI: 10.1093/annonc/mdv236.Peer-Reviewed Original ResearchConceptsVitamin D intakeDietary vitamin D intakePancreatic Cancer Case-Control ConsortiumPancreatic cancerD intakeVitamin DOdds ratioInternational Pancreatic Cancer Case-Control ConsortiumStudy-specific odds ratiosTotal vitamin D intakeMultivariable logistic regressionCase-control studyPancreatic cancer riskRandom-effects modelEstimates of associationDietary intakeCancer riskLogistic regressionCancerIntakeAdditional studiesPotential roleAssociationRiskNegative association
2014
Plasma Metabolite Biomarkers for the Detection of Pancreatic Cancer
Xie G, Lu L, Qiu Y, Ni Q, Zhang W, Gao YT, Risch HA, Yu H, Jia W. Plasma Metabolite Biomarkers for the Detection of Pancreatic Cancer. Journal Of Proteome Research 2014, 14: 1195-1202. PMID: 25429707, PMCID: PMC4324440, DOI: 10.1021/pr501135f.Peer-Reviewed Original ResearchCase–Control Study of Aspirin Use and Risk of Pancreatic Cancer
Streicher SA, Yu H, Lu L, Kidd MS, Risch HA. Case–Control Study of Aspirin Use and Risk of Pancreatic Cancer. Cancer Epidemiology Biomarkers & Prevention 2014, 23: 1254-1263. PMID: 24969230, PMCID: PMC4091763, DOI: 10.1158/1055-9965.epi-13-1284.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnti-Inflammatory Agents, Non-SteroidalAspirinCase-Control StudiesFemaleHumansIncidenceMaleMiddle AgedOdds RatioPancreatic NeoplasmsConceptsAspirin usePancreatic cancerLong-term aspirin useLow-dose aspirinCase-control studyCalendar time periodTime of interviewRisk-benefit analysisAspirin regimenCardiovascular diseaseReduced riskYear of interviewPossible associationCancerConnecticut StudyRegular useAspirinRiskCase frequencySignificant relationshipYearsRegimenComplicationsPrognosisMortalityHelicobacter pylori Seropositivities and Risk of Pancreatic Carcinoma
Risch HA, Lu L, Kidd MS, Wang J, Zhang W, Ni Q, Gao YT, Yu H. Helicobacter pylori Seropositivities and Risk of Pancreatic Carcinoma. Cancer Epidemiology Biomarkers & Prevention 2014, 23: 172-178. PMID: 24234587, PMCID: PMC3947155, DOI: 10.1158/1055-9965.epi-13-0447.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCase-Control StudiesChinaFemaleHelicobacter InfectionsHelicobacter pyloriHumansMaleMiddle AgedPancreatic NeoplasmsRisk FactorsConceptsCagA-positive strainsPancreatic cancerPancreatic carcinomaCagA seropositivityPylori seropositivityPylori colonizationGastric acidityH. pyloriLarge population-based case-control studyPopulation-based case-control studyPancreas cancer riskParticular cancer siteVirulence protein CagAHelicobacter pylori seropositivityH. pylori seropositivityBody mass indexH. pylori colonizationCase-control studyHelicobacter pylori colonizationH. pylori CagAStrain typesPathophysiologic actionsVenipuncture specimensAntibody seropositivityCase patients
2013
ABO Blood Group and Risk of Pancreatic Cancer: A Study in Shanghai and Meta-Analysis
Risch HA, Lu L, Wang J, Zhang W, Ni Q, Gao YT, Yu H. ABO Blood Group and Risk of Pancreatic Cancer: A Study in Shanghai and Meta-Analysis. American Journal Of Epidemiology 2013, 177: 1326-1337. PMID: 23652164, PMCID: PMC3732019, DOI: 10.1093/aje/kws458.Peer-Reviewed Original ResearchConceptsABO blood groupGroup BBlood groupPancreatic cancerNonendemic populationsGroup ASummary odds ratio (OR) estimatesGastric epithelial expressionPositive Helicobacter pyloriCagA-negative H. pylori strainsCytotoxin-associated genePancreatic cancer casesBlood group BOdds ratio estimatesH. pylori strainsPooled studiesCancer casesEpithelial expressionHigh riskB antigensGroup OSystematic reviewMeta-AnalysisHelicobacter pyloriPylori strains
2011
Genetic Effects and Modifiers of Radiotherapy and Chemotherapy on Survival in Pancreatic Cancer
Zeng H, Yu H, Lu L, Jain D, Kidd MS, Saif MW, Chanock SJ, Hartge P, Risch H. Genetic Effects and Modifiers of Radiotherapy and Chemotherapy on Survival in Pancreatic Cancer. Pancreas 2011, 40: 657-663. PMID: 21487324, PMCID: PMC3116071, DOI: 10.1097/mpa.0b013e31821268d1.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overATP Binding Cassette Transporter, Subfamily G, Member 2ATP-Binding Cassette TransportersCase-Control StudiesConnecticutDihydrouracil Dehydrogenase (NADP)FemaleGenetic MarkersGenetic VariationGenome-Wide Association StudyHumansMaleMiddle AgedNeoplasm ProteinsPancreatic NeoplasmsPolymorphism, Single NucleotidePrognosisProportional Hazards ModelsSerpinsSurvival AnalysisTreatment OutcomeConceptsPancreatic cancerOverall survivalCancer survivalProportional hazards regression modelsSurvival of patientsPopulation-based studyPancreatic cancer survivalHazards regression modelsGerm-line genetic variationEvidence of associationClinical outcomesCancer patientsTreatment outcomesTreatment responseSignificant associationPatientsCancerPrevious genome-wide association study dataRadiotherapyPutative markerGenetic polymorphismsSurvivalDPYD geneChemotherapyEvidence of interaction
2010
ABO Blood Group, Helicobacter pylori Seropositivity, and Risk of Pancreatic Cancer: A Case–Control Study
Risch HA, Yu H, Lu L, Kidd MS. ABO Blood Group, Helicobacter pylori Seropositivity, and Risk of Pancreatic Cancer: A Case–Control Study. Journal Of The National Cancer Institute 2010, 102: 502-505. PMID: 20181960, PMCID: PMC2902822, DOI: 10.1093/jnci/djq007.Peer-Reviewed Original ResearchMeSH KeywordsABO Blood-Group SystemAdultAgedAged, 80 and overAntibodies, BacterialAntigens, BacterialBacterial ProteinsCase-Control StudiesConfounding Factors, EpidemiologicConnecticutEnzyme-Linked Immunosorbent AssayFemaleHelicobacter InfectionsHelicobacter pyloriHumansIncidenceMaleMiddle AgedOdds RatioPancreatic NeoplasmsConceptsNon-O blood typeH pylori seropositivityCase-control studyPancreatic cancerPylori seropositivityABO blood groupEnzyme-linked immunosorbent assayBlood typeBlood groupPopulation-based case-control studyNon-O blood groupControl subjects frequencyH pylori colonizationVirulence protein CagAHelicobacter pylori seropositivityPancreatic cancer riskO blood typeRandom digit dialingCagA seropositivityCase patientsH pyloriControl subjectsRisk factorsPylori colonizationCancer risk